152 related articles for article (PubMed ID: 35313332)
1. Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder Cancer.
Huang KC; Chanda D; McGrath S; Dixit V; Zhang C; Wu J; Tendyke K; Yao H; Hukkanen R; Taylor N; Verbel D; Kim DS; Endo A; Noland TA; Chen Y; Matijevic M; Wang J; Hutz J; Sarwar N; Fang FG; Bao X
Mol Cancer Ther; 2022 Jun; 21(6):914-924. PubMed ID: 35313332
[TBL] [Abstract][Full Text] [Related]
2. BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.
Lombardo KA; Obradovic A; Singh AK; Liu JL; Joice G; Kates M; Bishai W; McConkey D; Chaux A; Eich ML; Rezaei MK; Netto GJ; Drake CG; Tran P; Matoso A; Bivalacqua TJ
J Pathol; 2022 Feb; 256(2):223-234. PubMed ID: 34731491
[TBL] [Abstract][Full Text] [Related]
3. Effect of different Bacillus Calmette-Guerin substrains on growth inhibition of T24 bladder cancer cells and cytokines secretion by BCG activated peripheral blood mononuclear cells of PBMCs.
Janaszek-Seydlitz W; Prygiel M; Bucholc B; Wiatrzyk A; Czajka U; Górska P; Soliwoda U
Adv Clin Exp Med; 2014; 23(6):877-84. PubMed ID: 25618112
[TBL] [Abstract][Full Text] [Related]
4. FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer.
Zhang Y; Huo F; Cao Q; Jia R; Huang Q; Wang ZA; Theodorescu D; Lv Q; Li P; Yan C
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35361729
[TBL] [Abstract][Full Text] [Related]
5. Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections.
van Puffelen JH; Novakovic B; van Emst L; Kooper D; Zuiverloon TCM; Oldenhof UTH; Witjes JA; Galesloot TE; Vrieling A; Aben KKH; Kiemeney LALM; Oosterwijk E; Netea MG; Boormans JL; van der Heijden AG; Joosten LAB; Vermeulen SH
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36693678
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
7. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
8. Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.
Garcia PV; Seiva FR; Carniato AP; de Mello Júnior W; Duran N; Macedo AM; de Oliveira AG; Romih R; Nunes Ida S; Nunes Oda S; Fávaro WJ
BMC Cancer; 2016 Jul; 16():422. PubMed ID: 27389279
[TBL] [Abstract][Full Text] [Related]
9. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
[TBL] [Abstract][Full Text] [Related]
12. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K
Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer.
Garris CS; Wong JL; Ravetch JV; Knorr DA
Sci Transl Med; 2021 May; 13(594):. PubMed ID: 34011627
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
[TBL] [Abstract][Full Text] [Related]
15. Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell-Mediated Tumor Regression in the MB49 Bladder Cancer Model.
Domingos-Pereira S; Sathiyanadan K; La Rosa S; Polák L; Chevalier MF; Martel P; Hojeij R; Derré L; Haefliger JA; Jichlinski P; Nardelli-Haefliger D
Cancer Immunol Res; 2019 Apr; 7(4):621-629. PubMed ID: 30696629
[TBL] [Abstract][Full Text] [Related]
16. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
17. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.
Roumiguié M; Kamat AM; Bivalacqua TJ; Lerner SP; Kassouf W; Böhle A; Brausi M; Buckley R; Persad R; Colombel M; Lamm D; Palou-Redorta J; Soloway M; Brothers K; Steinberg G; Lotan Y; Sylvester R; Alfred Witjes J; Black PC
Eur Urol; 2022 Jul; 82(1):34-46. PubMed ID: 34955291
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
19. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
